Developing AI tools to score cognitive tests for clinicians assessing brain function
Cognitive tests help neuropsychologists assess memory, attention and other mental functions in people with neurological or psychiatric conditions. Scoring paper tests and preparing reports manually takes time, limits assessment capacity and can produce differences between raters.
neurodAIgnostics is developing investigational AI tools that turn photographs of completed cognitive tests into scores and report suggestions. It aims to reduce scoring work while preserving familiar paper-based assessments and clinicians’ role in interpretation.
What stands out about neurodAIgnostics
neurodAIgnostics began a Dutch-language assessment pilot with Kenniscentrum Revalidatiegeneeskunde Utrecht in the Netherlands.
In June 2025, neurodAIgnostics secured an Innosuisse grant for cognitive scoring work with University Hospital Zurich and CSEM.
Co-founder Nicolas Langer researched childhood brain development at Harvard Medical School as a postdoctoral fellow in 2012–2013.
Co-founder Nicolas Langer became a University of Zurich associate professor in 2022 after six years researching brain plasticity there.
Co-founder Arnaud Bistoquet earned a Georgia Institute of Technology PhD researching machine learning for medical imaging.
neurodAIgnostics is a University of Zurich spin-off translating cognitive-assessment research into AI-assisted scoring and reporting tools.
In a 2024 study, the academic ROCF scoring model behind the platform achieved a mean absolute error of 1.13 in independent prospective validation.
neurodAIgnostics joined the 2026 Digital Health Accelerator cohort and was selected for Venture Leaders Medtech 2026’s Boston roadshow.
Co-founder Perrine Lhuillier received UZH Entrepreneur Fellowship support in 2025–2026 to advance neurodAIgnostics’ cognitive-assessment project.
The neurodAIgnostics founding team was selected for Venture Kick’s first support stage and awarded CHF 10,000 in January 2025.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.